🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

SBRT Followed by Ipilimumab N01, Sintilimab, Nab-Paclitaxel and Gemcitabine for Locally Advanced Pancreatic Cancer

RecruitingPhase 2Ages 18 Years - 75 YearsAllShandong Cancer Hospital and Institute
NCT07683221 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This is a Phase II, prospective, single-arm exploratory clinical trial designed to evaluate the efficacy and safety of stereotactic body radiotherapy followed by ipilimumab N01 plus sintilimab in combination with nab-paclitaxel and gemcitabine in patients with locally advanced pancreatic cancer. Eligible patients will receive SBRT followed by sequential systemic therapy. The primary endpoint is progression-free survival, and secondary endpoints include overall survival, disease control rate, duration of response, objective response rate, and safety.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Participants voluntarily agree to participate in the study, sign the informed consent form, and are willing and able to comply with study procedures and follow-up. * Histologically or cytologically confirmed pancreatic ductal adenocarcinoma. * Locally advanced unresectable pancreatic cancer without distant metastasis, confirmed by multidisciplinary team evaluation. * Age 18 to 75 years, inclusive. * Eastern Cooperative Oncology Group performance status of 0 to 1. * Life expectancy of at least 3 months. * No prior systemic therapy for advanced pancreatic cancer. * At least one measurable lesion according to RECIST 1.1. Exclusion Criteria: * Participation in another anti-cancer drug clinical trial within 4 weeks before enrollment. * Prior targeted therapy or prior treatment with immune checkpoint inhibitors. * Presence of distant organ metastasis, including liver, peritoneal, brain, or meningeal metastasis. * Pregnancy or breastfeeding. * Any condition that, in the investigator's opinion, makes the participant unsuitable for enrollment in this study.
💊

What it tests

  • SBRT + Ipilimumab N01 + Sintilimab + AG Chemotherapy
📍

Where

1 site
Shandong Cancer Hospital and Institute
Jinan, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy